A Food & Drug Administration advisory committee raised questions yesterday about the safety and effectiveness of a patch developed by Procter & Gamble to increase the sex drives of women. The committee will present its findings today to a panel of FDA officials. While not binding, the committee's recommendations typically serve as a bellwether for FDA approval. The committee cited a research study that concluded a combination of the hormones progesterone and estrogen increased the risk of heart and breast cancer, and wondered if a different hormone, such as the testosterone used in P&G's Intrinsa patch, would produce a similar...
